KRYS+logo+no_background+with+registered+symbol+.png
Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates
May 06, 2024 08:00 ET | Krystal Biotech, Inc.
Net product revenue of $45.3 million in 1Q and $95.9 million since AugustFirst patient dosed in inhaled KB707 study for locally advanced or metastatic tumors of the lungReceived Fast Track...
KRYS+logo+no_background+with+registered+symbol+.png
Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
May 02, 2024 07:00 ET | Krystal Biotech, Inc.
PITTSBURGH, May 02, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new...
KRYS+logo+no_background+with+registered+symbol+.png
Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024
April 26, 2024 07:00 ET | Krystal Biotech, Inc.
PITTSBURGH, April 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter...
KRYS+logo+no_background+with+registered+symbol+.png
Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung
April 22, 2024 07:00 ET | Krystal Biotech, Inc.
• Received Fast Track Designations for both inhaled and intratumoral KB707 PITTSBURGH, April 22, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage...
KRYS+logo+no_background+with+registered+symbol+.png
Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting
April 04, 2024 07:00 ET | Krystal Biotech, Inc.
PITTSBURGH, April 04, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new...
KRYS+logo+no_background+with+registered+symbol+.png
Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference
February 28, 2024 07:00 ET | Krystal Biotech, Inc.
PITTSBURGH, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the...
KRYS+logo+no_background+with+registered+symbol+.png
Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
February 26, 2024 08:00 ET | Krystal Biotech, Inc.
•  Net product revenue of $42.1M in 4Q and $50.7M for the year •  New England Journal of Medicine publication of the use of B-VEC eyedrop formulation •  Reached alignment with FDA to enable...
KRYS+logo+no_background+with+registered+symbol+.png
Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
February 20, 2024 07:00 ET | Krystal Biotech, Inc.
PITTSBURGH, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, will report its fourth quarter and full year 2023...
KRYS+logo+no_background+with+registered+symbol+.png
Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung
February 13, 2024 07:00 ET | Krystal Biotech, Inc.
• FDA clears IND and Phase 1 (KYANITE-1) clinical trial expected to be initiated in 1H 2024 PITTSBURGH, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a...
KRYS+logo+no_background+with+registered+symbol+.png
Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa
February 08, 2024 07:00 ET | Krystal Biotech, Inc.
• Initial clinical data suggest the potential of B-VEC to treat lesions in the eye of DEB patients and additional applications of Krystal’s HSV-1 platform to treat ocular diseases • Repeat...